

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

HOW KAYENTIS REDUCES THE CO2 EMISSIONS OF YOUR eCOA PROJECTS WITH ITS CARBON NEUTRAL PROGRAM

In 2020, we implemented a carbon neutral program for all our clinical trials
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines



1 WE EVALUATE THE CARBON FOOTPRINT OF EACH PROJECT

We take into account all CO2 emissions (scopes 1, 2 & 3) generated during each project (e.g. the production of devices used at clinical sites, the shipping of those devices, and any travel undertaken for project management purposes...) to evaluate the overall carbon impact

2 WE PROPOSE SOLUTIONS TO LIMIT PROJECT CARBON EMISSIONS



ECO-FRIENDLY DEVICE STRATEGY

According to study protocol, we are able to reduce the production, shipping and use of extra devices through:

- A BYOD hybrid strategy
- A WebCOA or Interview mode back-up option
- Refurbished devices / cross-patient reuse of devices within study



OPTIMIZED SHIPPING

To limit the carbon footprint of our shipping, we offer:

- The smallest size shipment boxes possible
- Recyclable cardboard
- Country-level shipments, if possible, to limit number of deliveries



VIRTUAL SUPPORT FOR PATIENTS & SITES

To reduce the carbon footprint of the study-associated travel, we have implemented:

- A Telemedicine app to facilitate study visits while reducing patient travel and supporting decentralized clinical trials
- A resource tool, Kayentis Media Player, available for patients to store training modules, user guides and educational resources



FONDATION
GoodPlanet

3 WE OFFSET RESIDUAL CO2 EMISSIONS

To go above and beyond, we offset the project carbon emissions that we are unable to reduce by making an equivalent monetary donation to the GoodPlanet Foundation's carbon solidarity action program

This program aims to combat climate change by developing sustainable and economically viable alternatives to polluting activities, to the benefit of the most disadvantaged groups: e.g. construction of solar ovens in Africa, replantation of degraded areas by establishing a sustainable agroforestry model in Ecuador, marine and coastal ecosystem conservation in Mauritius, and forest regeneration in Colombia

Kayentis aims to be a sustainable company in a sustainable world
As such, we support the pharma community's key ambitions to protect the environment

Let us know if you need any more information!



Boston - USA | Meylan - France | Tokyo - Japan

Download the infographic

Ask for more information



[Learn more:](#)



The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

5 February 2024

In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy

[Read More »](#)



The relevance of ePROs in early phase clinical trials

31 January 2024

Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the

[Read More »](#)



3 considerations to take into account when setting up an eCOA clinical trial

29 January 2024

In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains

[Read More »](#)



Kayentis operational excellence

23 January 2024

Why do customers recommend Kayentis for operational excellence? More than 95% of Kayentis customers recommend

[Read More »](#)




Innovation and Partnerships: The Biotech Perspective

16 January 2024

In the ever-evolving landscape of biotechnology, groundbreaking advancements continue to shape the future of healthcare.

[Read More »](#)



Exploring The Specific Challenges Of Pediatric Clinical Trials – Insights From Site Experts

22 November 2023

In this first episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)